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disease, infecting 185,000,000 persons, i.e. 2.8% of the world
population, and causing 350,000 deaths annually [1]. Chronic
hepatitis C relentlessly leads to increasing degrees of ﬁbrosis
and ultimately cirrhosis. The ﬁbrosis progression rate is variable,
with some patients progressing to cirrhosis within a few years,
while others may never progress even after decades from infec-
tion, depending on the presence and type of host, viral and envi-
ronmental factors [2]. Although many of these factors cannot be
modiﬁed [2], the ﬁbrosis progression of hepatitis C can be effec-
tively stopped with potent antivirals, leading to HCV eradication
[3]. On the other hand, modiﬁcation of the natural history of
hepatitis C, by modulating the ﬁbrogenic process, independently
of any intervention on HCV, has so far been a chimera, despite
intense preclinical research efforts. More in general, the clinical
development of antiﬁbrotics has been lagging behind, and no
effective drugs have been validated in the clinical setting [4].
Statins may have some antiﬁbrotic activity in pulmonary [5]
and cardiac [6] ﬁbrosis, although the mechanisms of these pur-
ported beneﬁcial effects are undeﬁned. Furthermore, there is
some limited evidence on the antiﬁbrotic effect of statins in
experimental rat models of liver ﬁbrosis [7,8], while clinical trials
in patients with non-alcoholic fatty liver disease have been dis-
couraging [9].
Simon et al. [10] analysed the association between statin use
and liver ﬁbrosis progression in a well-characterized cohort of
chronic hepatitis C patients enrolled in the HALT-C trial [11].
All patients had advanced liver ﬁbrosis (Ishak ﬁbrosis score
P3) at entry as well as a history of virological non-response to
standard interferon therapies. After 24 weeks of retreatment with
peginterferon alfa-2a and ribavirin, patients were randomizedJournal of Hepatology 20
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Open access under CC BY-NC-ND license.based on their virological response at week 20: those with detect-
able serum HCV RNA were assigned for the next 3.5 years to
either a maintenance therapy with 90 lg of peginterferon alfa-
2a weekly without ribavirin or to an untreated control group.
One of the goals of this trial was to evaluate whether a low dose
of interferon-alpha maintenance therapy could improve histolog-
ical outcomes independently of antiviral effects [11], by centrally
assessing serial liver biopsies performed at enrolment and 1.5
and 3.5 years after randomization. In the study by Simon et al.
[10], the use of statins was ascertained as part of a comprehen-
sive medical history, obtained at enrolment and in the course
of the study. Thus, a total of 543 patients with serial liver biopsies
could be evaluated: 29 had received continuous statin therapy
throughout the study, while 514 did not, thus serving as controls.
Liver ﬁbrosis progression occurred in 3 of 29 (10%) statin users
and in 145 of 514 (29%) non-users. The hazard ratio for ﬁbrosis
progression among statin users compared to non-users was
0.31 (95% CI 0.10–0.97), after adjustment for a few of the known
predictors of progression, such as body mass index, platelets and
hepatic steatosis. In addition, the average change in the Ishak
ﬁbrosis score across the whole study period was 0.34 (SE
0.18) for statin users compared to +0.42 (SE 0.07) for non-users.
Histological activity score or alanine aminotransferase level
changes were not statistically different between statin users
and non-users. The authors concluded that statin use is associ-
ated with a reduced risk of the liver ﬁbrosis progression rate in
chronic hepatitis C patients with advanced ﬁbrosis, and that this
beneﬁcial effect does not appear to be mediated by a decrease in
the level of liver inﬂammation.
Statins are extensively used in clinical practice for both pri-
mary and secondary prevention of cardiovascular events in
patients with coronary artery diseases, diabetes mellitus and
other atherosclerotic disorders. Statins exert their effect primar-
ily via inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme
A reductase, a transmembrane protein catalyzing a rate-limiting
step in the mevalonate pathway that leads to the synthesis of iso-
prenoids and sterols. The major and best known effect of this
inhibitory action is the reduction of circulating cholesterol.
However, many beneﬁcial effects of statins seem independent
of cholesterol level reduction. These pleiotropic effects of statins
include anti-inﬂammatory, immunomodulatory, antibacterial,15 vol. 62 j 8–10
JOURNAL OF HEPATOLOGY
antiproliferative, antioxidant effects as well as the improvement
of endothelial function and the suppression of platelet aggrega-
tion (reviewed in [12]).
On one hand, pleiotropic effects of statins are still secondary to
the blockade of the mevalonate synthesis. This leads in fact to an
impaired production of lipophilic prenyl compounds, involved in
the post-translational modiﬁcation of several factors, such as
some small GTP-binding proteins (e.g. Rho, Rac, and Ras) and
other proteins, whose localization to cell membranes depends
on their isoprenylation [6,12]. In addition, impaired sterol synthe-
sis may alter the composition of rafts, thus interfering with cell
signalling and apoptosis, which may account, in part, for their
antitumour effects [13]. Indeed, statins have been shown to
reduce cancer-related mortality in several studies, including the
vast survey on the Danish Civil Registration System database
[14], and also to reduce the risk of hepatocellular carcinoma
(HCC) in patients with chronic hepatitis C [15] or chronic hepatitis
B [16]. On the other hand, also mevalonate-independent mecha-
nisms seem to be involved. For example, a recent, interesting
study showed that statins increased small GTP-binding protein
GDP dissociation simulator (SmgGDS) in cultured human endo-
thelial cells [17]. Adding prenyl compounds failed to counteract
the SmgGDS increase. This effect explained the statin-associated
protection against angiotensin II-induced medial thickening of
coronary arteries and ﬁbrosis in a mouse model [17]. SmgGDS
favours degradation of the intracellular factor Rac1, thus blocking
its induction of reactive oxygen species and providing a mecha-
nismwhereby statins may reduce oxidative stress [6], an interest-
ing observation that may in part explain the antiﬁbrotic effect of
statins. Concerning the latter, Simon et al. [10] discuss some
potential, additional mechanisms, such as activation of the Krup-
pel-like factor 2 in endothelial cells, which may lead to an
enhanced transcription of vasoprotective genes, but clearly the
ﬁne details linking statins and ﬁbrogenesis warrant further work.
The study of Simon et al. [10], although intriguing, has limita-
tions as duly acknowledged by the authors. First, the low number
of outcomes among statin users (3 out of 29) limited the ability to
test for all potential confounders and the scope of the multivari-
able analysis that was conducted. Thus, these results should be
considered as preliminary, and warrant a validation in additional
studies with larger sample sizes and a greater number of out-
comes. Second, the HALT-C trial included only patients with
advanced liver ﬁbrosis and in whom interferon was not contrain-
dicated, i.e. a very selected population. More data is warranted in
patients with milder ﬁbrosis stages. Third, no dose effect could
be assessed since the dose of statins used by study participants –
a crucial parameter to assess a causal link with a clinical outcome
–wasnot recorded. In addition, statinsmayhave exerted their pro-
tective effect indirectly, i.e. via the suppression of HCV replication.
Indeed, statins exert some degree of antiviral effect on HCV both
in vitro and in vivo, especially when added to standard doses of
interferon-a and ribavirin [18]. However, when the authors ana-
lysed the change in viral load over the study period, the median
decline in HCV RNA was comparable among statin users and
non-users, even after adjustment for randomization to the
treatment or observation group. This suggests that the low dose
interferon used in HALT-C was probably insufﬁcient to produce
any meaningful antiviral effect, and that therefore the reduction
of HCV replication could not be a confounder in their study.
Another caveat that should caution against a wider use of stat-
ins consists of the fact that any purported beneﬁcial effect shouldJournal of Hepatology 2be carefully weighed against the potential side effects of a long
term statin use. Although the reported cases of signiﬁcant hepa-
totoxicity are rare [19], statins, particularly the lipophilic ones
(simvastatin, lovastatin and the blockbuster atorvastatin), still
present some safety concerns, such as the risk of myopathies,
renal dysfunction, cognitive and behavioural dysfunction (includ-
ing memory loss), and – possibly – the development of diabetes
mellitus [20]. In addition, drug-drug interactions may limit their
use in patients with several comorbidities [20].
Thus, as usual, a word of caution is mandatory before we draw
ﬁrm conclusions. For a hepatologist’s point of view, statins may
well reduce the degree of portal hypertension [21] and the risk
of HCC in cirrhotic patients [15,16], but for these indications
and as antiﬁbrotic agents we need more data. Nevertheless, the
paper by Simon and collaborators has the great merit of provid-
ing the basis for prospective cohort validation studies and
intriguing working hypotheses that may (or may not) make stat-
ins, already among the top selling drugs of all times, a true rem-
edy for all seasons, given their numerous beneﬁcial effects in
several ﬁelds of medicine other than hepatology.Conﬂict of interest
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